Clinical and experimental studies provide substantial evidence for the importance of the cholinergic system in learning and memory. Scopolamine, a cholinergic antagonist, causes a memory impairment in normal subjects.' This deficit can be partially reversed by physostigmine, an anticholinesterase inhibitor. Animals with lesions of the basal forebrain cholinergic nuclei, which provide much of the cortical cholinergic input, have difficulty learning.2 Aged rats with evidence of cholinergic neuronal loss learn less well than younger rats, but improve after fetal cholinergic neuron transplants.' Patients with rupture of anterior communicating artery aneurysms are frequently amnestic, either because of diffuse cerebral damage4 or because of damage to the basal forebrain. 5 Finally, in Alzheimer's disease, in which amnesia is a prominent clinical feature, there is cholinergic neuronal loss in the basal forebrain,6 as well as decreases of cortical cholinergic markers.7
The high prevalence of Alzheimer's disease has led to an extensive search for therapeutic agents that might reverse the observed cognitive impairments. If a cholinergic deficiency can cause amnesia and patients with Alzheimer's disease who are amnestic have a cholinergic deficiency, then cholinergic augmentation would potentially reverse or ameliorate the memory disorder. This logic has resulted in numerous clinical trials using drugs to augment the cholinergic system. Perhaps the most extensive experience to date has been with physostigmine, and the results have been equivocal.>'0 Patients respond in a variable manner, and reports of efficacy of this drug are not consistently replicated." Even when memory improvement has been reported, the results have been modest and of dubious clinical significance.
The efficacy of cholinergic augmentation in Alzheimer's disease may be limited because mechanisms other than cholinergic deficiency contribute to the amnesia in this disease. Patients are also deficient in other neurotransmitters including noradrenaline, serotonin and somatostatin."2 Noradrenaline may also play a role in the modulation of memory and learning."3 The relative contributions of other neurotransmitters lost in Alzheimer's disease to memory functioning is not well understood. If they do play a modulatory role, then cholinergic augmentation alone may be inadequate to reverse a memory deficit. A second reason for the inadequacy of cholinergic augmentation in the treatment of amnesia in Alzheimer's disease may be functional consequences of the neuropathologic topography in the disease.'4 Senile plaques and fibrillary tangles are found in high concentrations in the dentate gyrus and the subiculum. The dentate gyrus provides the major input to the hippocampus via the perforant pathway, and the subiculum provides the major output of the hippocampus. The hippocampus itself is a critical structure for normal memory functioning,"5 and location of structural neuropathology at its major input and output sites may effectively isolate it from the rest of a larger scale neural network mediating memory. Cholinergic replacement would not alter this structural pathology, and therefore the memory improvement, if any, would be modest.
We recently had the opportunity to study a densely amnestic man with a discrete lesion primarily located at the right diagonal band of Broca."6 As the diagonal band of Broca provides much of the cholinergic input to the Figure 1 Axial (a), coronal (b) and sagittal (c) slices ofMRI scan, showing postsurgical lesion in the right basalforebrain hippocampus,'7 it is likely that his amnesia resulted from a cholinergic deficiency within the septal-hippocampal circuit. In the absence of a prior history of dementia, it is unlikely that he had pathological neuronal loss in the locus coeruleus or dorsal raphe with consequent noradrenergic or serotonergic deficiencies. It is also unlikely that he had accumulations of senile plaques or neurofibrillary tangles contributing to cognitive impairment. For these reasons, he provided an unusual opportunity to learn if dense amnesia as a consequence of a specific cholinergic deficiency can be ameliorated by cholinergic augmentation. The study was conducted in two phases, an open best-dose finding phase, followed by a double-blind, placebo-controlled trial on his best dose. A third phase of the study, which would have included a double-blind, two week "on", two week "off" period was planned, but was not carried out because the patient died. During the first phase of the study, he also had single photon emission tomography (SPECT) at baseline, and on physostigmine.
Case report A 52-year-old, right-handed man had a 25-year history of poorly controlled, partial complex seizures. MRI revealed a small mass lesion in the right medial basal forebrain thought to be consistent with a low grade glioma. His case history and neuropsychological testing have been reported in detail elsewhere. '6 In brief, he underwent surgery for this mass lesion. A 1 x 1-5 cm mass consistent with a low grade, microcystic astrocytoma was resected just posterior to the right gyrus rectus. After surgery the patient had a dense amnesia associated with confabulation.
Postsurgical MRI revealed a small discrete lesion primarily confined to the basal forebrain, right of midline ( fig 1) . The lesion was localised to the diagonal band of Broca, the anterior hypothalamus, the preoptic area, the paraterminal gyrus, and the lamina terminalis. ' Assessment battery A subset of the measures obtained at baseline was selected for repeated administration during the dose-finding phase of the study. Table 3 shows measures of supraspan verbal learning, attention span, attentional vigilance, distractibility, and verbal fluency.27 30 31 Multiple parallel forms were necessary for each measure included in the daily assessment battery. The California Verbal Learning Test27 was used to assess verbal learning only at baseline. A set of parallel word lists containing 16 nouns (Bowers and Verfaellie, unpublished test) was used for daily testing. Each list was matched for mean frequency, concreteness, and imageability."" Administration was identical to the verbal list learning test, with five learning trials followed by a 30 minute delayed recall. Unlike the verbal list learning test, however, these lists were not designed for semantic categorization. Alternate forms of Digit Span and the Auditory Consonant Trigrams test were created by generating random number and consonant groupings, excluding groupings that provided an obvious encoding advantage (e.g., "2468" or "NBC"). Four parallel forms of the Controlled Oral Word Association test were created, balancing for the verbal associative frequency correlated with specific letters.34 Each of these forms was administered twice. To assess vigilance and distractibility, the Gordon Diagnostic System30 permits two different target stimulus sequences; these were administered on alternate days. Tests were administered in a standardized order each day, after the fifth physostigmine dose.
Assessment results
The patient's performance on the verbal list learning task during eight days of increasing doses of physostigmine followed an inverted U-shaped curve (fig 2) . His optimal performance on the supraspan list learning task occurred at doses of 3-0 mg and 3-5 mg of physostigmine every two hours. At these two doses, his maximum single trial recalls of 10 and 11 significantly exceeded his typical Digit Span score of six or seven. This level of performance had not been observed in multiple evaluations over the previous 18 months. At 1.0 mg, 1-5 mg, and 4.0 mg his performance showed a decline. We are uncertain if his performance at these doses represents a decline from baseline. His delayed recall of these lists remained severely impaired throughout the trial. His performance on measures of attention span, attentional vigilance, distractibility, (fig 3) . He immediately recalled an average of 8 faces on physostigmine and 7-3 on placebo, and 6-3 (6 is a chance performance) on delay for both conditions. For story recall, he immediately remembered an average of 6-5 bits of information on physostigmine and 8-0 bits on placebo, and nothing in either condition after a 30 minute delay. Other cognitive tasks administered as part of the assessment battery-that is, measures of attention, psychomotor speed, generativity, and abstract thinking-were similarly unaffected by physostigmine. 
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Discussion
We report results of pharmacological treatment of a densely amnestic man, who had a surgical lesion primarily localised to the right diagonal band of Broca, although parts of the anterior hypothalamus were also involved.
The most likely cause of his amnesia was the disruption of the septal-hippocampal circuit. 16 The diagonal band of Broca has major cholinergic projections to the hippocampus,17 which are important for normal hippocampal electrophysiological functioning,44 and this septal-hippocampal circuit may be a critical cholinergic subcomponent for normal mem-ory functioning. Because he did not have a premorbid dementia, the patient provided an unusual opportunity to test the hypothesis that pathologic cholinergic deficiency causing amnesia can be reversed by pharmacologic cholinergic augmentation. The therapeutic trial failed to demonstrate a reversal or dramatic improvement in the amnesia. Although there was a suggestion of improvement in supraspan immediate recall of list items during the first phase of the study, this finding was not replicated in the second phase of the study. At no point was there convincing evidence that he was able to recall much information after a delay.
Some variability in responsiveness to treatment of patients with Alzheimer's disease may relate to the bioavailability of physostigmine to the brain.45 Although it is possible that this patient had not adequately absorbed physostigmine or that the absorbed medication did not gain entry into the central nervous system, both behavioural and SPECT data argue against this possibility. During the dose-finding phase, his response on immediate recall of word lists followed an inverted U-shaped curve, with the optimal dose being 3 0 or 3-5 mg of physostigmine every two hours. His pattern of improvement, better verbal free recall with an unchanged digit span, is consistent with the pattern of impairment induced in normal subjects by cholinergic blockade-that is, decreased verbal recall with a normal digit span. reports, before treatment, this patient had decreased activity in the medial temporal area ipsilateral to his diagonal band lesion. On a dose of 3-5 mg of physostigmine there was a reversal of the relative activity in the right compared with the left in the medial temporal region and not in any of the control regions of interest. Although it is not possible to be certain of our hippocampal localisation, it is difficult to explain why such a reversal of flow would have occurred in any adjacent region. These SPECT scans provide evidence that physostigmine did induce changes in blood flow in regions predicted, based on the neuroanatomy of his lesion. There was an unanticipated asymmetry noticed in the frontal operculum, with the right having markedly decreased blood flow both before and during treatment. It is possible that there was mechanical damage to this region from the surgical retraction of the frontal operculum that was not evident on the MRI scan.
Alternatively, because the medial forebrain bundle courses through the region of the diagonal band, some ascending noradrenergic or serotonergic fibres may have been disrupted, resulting in decreased blood flow that was not affected by cholinergic augmentation.
During the dose-finding phase of the study there was the suggestion of improvement in supraspan immediate recall of word lists at physostigmine doses of 3 0 and 3-5 mg. No difference was found in the double-blind, placebo-controlled trial. The placebo-controlled trial had several methodological limitations that need to be emphasised. The patient was unwilling to be in hospital for longer than a week, allowing only three days 'on' and three days 'off' the drug. The number of times he could be tested was limited, restricting the statistical power available to test for differences. Additionally, physostigmine pharmacodynamics within the CNS may have been a factor confounding our results. Although the serum half life is less than 30 minutes,47 CNS effects may be longer and more variable. Thal et a18 reported that some patients with Alzheimer's disease that appeared responsive to oral physostigmine required up to 36 hours after their last dose for their test scores to return to baseline. It remains possible that on this patient's 'off' days that followed his 'on' days, he had not yet fully cleared the CNS effects of physostigmine. We were aware of these methodological limitations and had planned a third phase with a longer two week 'on', two week 'off, double-blind placebo-controlled trial, allowing a more stable chemical state, and better assessment of the effects of cholinergic augmentation on his mnemonic abilities. Two weeks after the second phase of this study, however, he suddenly had a myocardial infarction and died before the third phase was initiated. We think it highly unlikely that physostigmine contributed to his cardiac arrest, two weeks after his last dose. We were not able to do a postmortem examination. Regardless of these methodological limitations, at no time during either phase of the study was there a dramatic improvement in his delayed memory recall.
Even under optimal conditions, there are at least two reasons why this patient may have had minimal benefit from physostigmine. First, the diagonal band of Broca, besides having cholinergic projections to the hippocampus, also has significant projections that respond to y-aminobutyric acid (GABA)." GABAergic systems interact with the basal forebrain cholinergic neurons by regulating cholinergic activity. 48 The effects of benzodiazepines are mediated through GABA receptors, and these classes of drugs have amnestic effects that are similar to anticholinergic agents. 49 The functional significance of the specific diagonal band GABAergic projections to medial temporal structures is not known. It is possible that a critical balance between cholinergic and GABAergic inputs is required for proper hippocampal functioning. Such a balance would not be achieved by simple cholinergic augmentation, limiting functional improvement.
Second, for fundamental theoretical reasons, based on how memory networks are thought to be organised, synaptic cholinergic augmentation might not serve to resurrect a memory system that is dysfunctional because of a presynaptic cholinergic deficiency. There has been recent interest in the probable parallel and distributed nature of information processing and representation in memory systems.505' Large scale networks consisting of tightly interconnected local networks contribute to the integrity of memory processes. These local networks include the basal forebrain, medial temporal structures, and thalamic nuclei. Damasio5" has hypothesised that memory retrieval involves the reactivation of widely distributed neural structures, even including unimodal association cortices. Parts of the hippocampal formation act as a convergence zone, receiving feed-forward information from association cortices and then reactivating extra limbic structures in a feed back fashion. If principles inherent in distributed models exemplified by Damasio's proposal are biologically valid, effectively evoking a memory would involve the coordination of a specific pattern of firing with both spatial (which brain structures are activated) and temporal (in what order they are activated) characteristics. Cholinergic augmentation with physostigmine increases the synaptic concentration of acetylcholine and increases the likelihood of postsynaptic firing. A global increase in synaptic acetylcholine is unlikely to recreate specific synaptic fluctuations of acetylcholine concentration that result from a normal pattern of presynaptic neuronal firing. Simply increasing the probability of postsynaptic firing, without specific control of its temporal pattern, may be insufficient to restore hippocampal function in encoding and retrieving specific memories. It would be analogous to attempting to fix a defective Morse telegraph, by increasing the ability to transmit 'dots' and 'dashes' without being able to recreate specific patterns of 'dot' and 'dash' transmission. Despite transmission of more noise, the message contained in the pattern of transmission would still be incomprehensible.
Damage to parallel distributed networks causes a graceful degradation of function.5' This property Qf these systems means that with close approximations of the original activation state, the original memory might be recreated. There may be a threshold of minimal cholinergic damage in which memory impairment could be benefited by cholinergic augmentation. With damage beyond this threshold, however, synaptic cholinergic augmentation might be inadequate to recapitulate specific patterns of activation necessary to retrieve specific memories. The minimal improvement in immediate recall seen in our patient in phase 1 of the trial and reports of modest improvement in some patients with Alzheimer's disease suggest minimal upgrading of memory systems by cholinergic augmentation. Perhaps this minimal upgrading helps in immediate recall of transiently formed memory representations, representations that are too fragile to withstand dissolution over time.
